Abstracts tagged "gout"

Abstract Number: 1581 • ACR Convergence 2022
Presence of Sonographic Crystal Deposits and Power-Doppler Signal in Patients with Gout Fulfilling Remission Criteria: A Multicenter Study
Nalia Domínguez-Lirón¹, Eugenio De Miguel², Agustín Martínez-Sanchis³, Diana Peiteado², Blanca Garcia-Magallon⁴, Esther Vicente-Rabaneda⁵, Enrique Calvo⁶, Basilio Rodríguez⁷, Alejandro Prada⁸, Boris Anthony Blanco Cáceres⁹, José Antonio Bernal¹⁰, Francisca Sivera¹¹, Santos Castañeda⁵, Sonia Mínguez⁷, Laura Barrio⁸, Mónica Vázquez-Díaz⁹, José Miguel Senabre¹², Cristina Bohorquez¹³ and Mariano Andrès³, ¹Miguel Hernández University, Alicante, Spain, ²Hospital Universitario La Paz, Madrid, Spain, ³Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ⁴Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ⁵Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁶Hospital Universitario Infanta Leonor, Madrid, Spain, ⁷Althaia Xarxa Assistencial Universitaria De Manresa, Manresa, Spain, ⁸Hospital Universitario de Torrejon, Madrid, Spain, ⁹Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹⁰Hospital Marina Baixa (Villajoyosa), Alicante, Spain, ¹¹Hospital Universitario de Elda, San Vicente del Raspeig, Spain, ¹²Hospital Marina Baixa, Villajoyosa, Spain, ¹³University Hospital Príncipe de Asturias, Immune System Diseases-Rheumatology Service, Alcalá de Henares, Madrid, Spain
Background/Purpose: The applicability of the preliminary remission criteria for gout [PMID 26414176] in clinical practice is unknown. This study evaluates the sonographic prevalence of monosodium…
Abstract Number: 1798 • ACR Convergence 2022
Health-Related Quality of Life Improvements Resulting from a Treat-to-Target Strategy in the Management of Gout: Post- Hoc Analysis of a Multicenter, Randomized, Double-Blind, Non-Inferiority Trial
Lindsay Helget¹, James O'Dell¹, Jeff Newcomb¹, Maria Androsenko², Mary Brophy², Anne Davis-Karim³, Bryant England¹, Ryan Ferguson², Michael Pillinger⁴, Tuhina Neogi⁵, Paul Palevsky⁶, Hongsheng Wu² and Ted Mikuls⁷, ¹University of Nebraska Medical Center, Omaha, NE, ²VA Boston Cooperative Studies Program Coordinating Center, Boston, MA, ³VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, ⁴NYU Grossman School of Medicine, New York, NY, ⁵Boston University School of Medicine, Boston, MA, ⁶University of Pittsburgh School of Medicine, Pittsburgh, Pittsburgh, ⁷Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The ACR recommends a treat-to-target strategy in gout management, centered on the titration of urate lowering therapy (ULT) to a goal serum urate (SU)…
Abstract Number: 1816 • ACR Convergence 2022
Assessing Urate Deposition and Inflammation in the Vasculature of Gout Patients Using Dual Energy Computed Tomography and Positron Emission Tomography Pre and Post Pegloticase- a Pilot Study
Ira Khanna, Venkatesh Mani, Renata Pyzik, Audrey Kaufman, Wei Wei Chi, Emilia Bagiella, Philip Robson and Yousaf Ali, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Gout is the most common inflammatory arthritis, caused by hyperuricemia and subsequent deposition of aggregated monosodium urate (MSU) crystals in both articular and extra-articular…
Abstract Number: 1582 • ACR Convergence 2022
Allopurinol Use and Risk of Acute Coronary Syndrome in Patients with Incident Gout: A Population-based Study in Sweden
Panagiota Drivelegka¹, Lennart Jacobsson², Karin Bengtsson³ and Mats Dehlin⁴, ¹Department of Rheumatology, Sahlgrenska University Hospital, Gothenburg, Sweden, ²Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden, ³Department of Rheumatology and Inflammation research, University of Gothenburg, Salhgrenska Academy, Gothenburg, Sweden, ⁴Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Gout is associated with an increased risk of cardiovascular disease, with accumulated evidence that gout is an independent risk factor. Whether allopurinol use alters…
Abstract Number: 1799 • ACR Convergence 2022
Evaluation of Adherence to and Agreement with the 2020 American College of Rheumatology Guideline for the Management of Gout by US Rheumatologists
Naomi Schlesinger¹, Michael Pillinger² and Peter Lipsky³, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²NYU Grossman School of Medicine, New York, NY, ³AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: The American College of Rheumatology (ACR) developed an updated guideline in 2020 for the management of gout.1 This study evaluates US rheumatologists' stated adherence…
Abstract Number: 1818 • ACR Convergence 2022
Hepatic Steatosis and Fibrosis in Patients with Gout Detected by Elastography
Naomi Schlesinger¹, ankoor patel¹, Vinod Rustgi¹, Anthony Yeo² and Peter Lipsky³, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Horizontherapeutics, New York, NY, ³AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Gout is associated with non-alcoholic fatty liver disease (NAFLD), but neither the frequency nor severity of NAFLD in gout is well described. Elastography is…
Abstract Number: 0001 • ACR Convergence 2022
12-month Findings of the Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR RCT)
John Botson¹, kenneth saag², Jeff Peterson³, Katie Obermeyer⁴, Brian LaMoreaux⁴, Suneet Grewal⁵, Amar Majjhoo⁶, John Tesser⁷ and Michael Weinblatt⁸, ¹Orthopedic Physicians Alaska, Anchorage, AK, ²University of Alabama at Birmingham, Birmingham, AL, ³Western Washington Arthritis Clinic, Seattle, WA, ⁴Horizon Therapeutics plc, Deerfield, IL, ⁵East Bay Rheumatology Medical Group, Inc., San Leandro, CA, ⁶Shores Rheumatology, PC, Troy, MI, ⁷Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁸Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The MIRROR RCT trial examined pegloticase (PEGylated uricase) safety and efficacy with methotrexate (MTX) vs placebo (PBO) as co-therapy. Sustained urate-lowering rate during Month…
Abstract Number: 1583 • ACR Convergence 2022
Race and Disease Severity Predict Reduced Response to Treat-to-Target Urate Lowering Therapy in Gout: Post-hoc Analysis of a Multicenter, Randomized, Double-Blind, Non-Inferiority Trial
Lindsay Helget¹, James O'Dell¹, Jeff Newcomb¹, Maria Androsenko², Mary Brophy², Anne Davis-Karim³, Bryant England¹, Ryan Ferguson², Michael Pillinger⁴, Tuhina Neogi⁵, Paul Palevsky⁶, Hongsheng Wu² and Ted Mikuls⁷, ¹University of Nebraska Medical Center, Omaha, NE, ²VA Boston Cooperative Studies Program Coordinating Center, Boston, MA, ³VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, ⁴NYU Grossman School of Medicine, New York, NY, ⁵Boston University School of Medicine, Boston, MA, ⁶University of Pittsburgh School of Medicine, Pittsburgh, Pittsburgh, ⁷Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The ACR recommends a treat-to-target strategy in the management of gout, involving titration of urate lowering therapy (ULT) to a serum urate (SU) goal…
Abstract Number: 1800 • ACR Convergence 2022
Successful Establishment of Chronic Gouty Arthritis Model in C57BL/6 Mice
Yue Yin¹, Yun Zhang¹, Hong Di¹, Xinxin Han¹ and Xuejun Zeng², ¹Peking Union Medical College Hospital, Beijing, China, ²Department of General Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China
Background/Purpose: Gout is an inflammatory disease caused by the deposition of MSU crystals in joints and other parts. At present, little progress in the research…
Abstract Number: 1820 • ACR Convergence 2022
Targeted Plasma Lipidomics Distinguishes Patients with Gout and Hyperuricemia from Controls
Blanka Stiburkova¹, Kateřina Pavelcová¹, Jana Bohatá¹, Karel Pavelka², Lenka Hasíková¹, Jakub Závada¹, Aleš Kvasnička³, Dana Dobešová³ and David Friedecký³, ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic, ³Palacky University Olomouc, Olomouc, Czech Republic
Background/Purpose: Gout is the most common type of inflammatory arthritis, characterised by chronic deposition of uric acid crystals in the joints, affecting approx. 1-2% of…
Abstract Number: 0112 • ACR Convergence 2022
What Drives Racial Disparities in Gout in the USA? – Population-Based, Sex-Specific, Casual Mediation Analysis
Natalie McCormick¹, Leo Lu², Chio Yokose³, amit johi⁴, Tony Merriman⁵, kenneth saag⁶, Yuqing Zhang⁷ and Hyon Choi⁸, ¹Massachusetts General Hospital, Boston, MA, ²Arthritis Research Canada, Vancouver, BC, Canada, ³Massachusetts General Hospital, Waltham, MA, ⁴Regeneron, Boston, MA, ⁵University of Otago, Dunedin, New Zealand, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷Massachusetts General Hospital, Quincy, MA, ⁸MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Emerging US cohort data suggest gout and hyperuricemia impart larger burdens on adults self-reporting Black race, especially Black women, than those self-reporting White race.[1,2]…
Abstract Number: 1633 • ACR Convergence 2022
Genetic Risk, Adherence to a Healthy Lifestyle, and Incident Gout in US Women and Men
Kehuan Lin¹, Natalie McCormick¹, Leo Lu², amit johi³, Chio Yokose⁴ and Hyon Choi⁵, ¹Massachusetts General Hospital, Boston, MA, ²Arthritis Research Canada, Vancouver, BC, Canada, ³Regeneron, Boston, MA, ⁴Massachusetts General Hospital, Waltham, MA, ⁵MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Lifestyle and genetic factors have been independently related to incident gout risk. However, it remains unknown whether the genetic risk of gout is affected…
Abstract Number: 1802 • ACR Convergence 2022
The Utility of Dual-energy Computed Tomography in Gout Patients During Urate Lowering Therapy
Min Jung Kim¹, Mi Hyeon Kim², SE RIM CHOI², Youjin Jung², Ji In Jung², Ju Yeon Kim², Jee Won Chai³ and Kichul Shin⁴, ¹Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, Republic of Korea, ²Seoul National University Hospital, Seoul, Republic of Korea, ³Seoul Metropolitan Government–Seoul National University Boramae Medical Center, Seoul, Republic of Korea, ⁴Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea
Background/Purpose: To investigate whether monosodium urate (MSU) deposition measured by dual-energy computed tomography (DECT) could help predict acute flares after discontinuing colchicine prophylaxis in patients…
Abstract Number: 1821 • ACR Convergence 2022
Colchicine and Other Gout Medications and the Risk of COVID-19 Infection, Hospitalization, and Subsequent Outcomes in People with Gout
Jasvinder singh¹, Timothy Bergquist², Vithal Madhira³ and Alfred Anzalone⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Sage Bionetworks, Seattle, WA, ³Palila Software, L.L.C., Reno, NV, ⁴University of Nebraska Medical Center, Ohama, NE
Background/Purpose: To examine whether the use of colchicine and other gout medications is associated with the risk of COVID-19 infection, hospitalization, and subsequent outcomes in…
Abstract Number: 0118 • ACR Convergence 2022
Sex-Based Variations in Emergency Department Utilization by Persons with Inflammatory Arthritis Conditions
Cheryl Barnabe¹, Patrick McLane², Nadia Luca¹, Katie Lin¹, Kelsey Chomistek¹, Meghan Elliott¹, Shanon McQuitty³, Eileen Davidson³, Clare Hildebrandt⁴, Steven Katz², Brian Holroyd² and Claire Barber¹, ¹University of Calgary, Calgary, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Patient and Family Advisors, Alberta Health Services, Calgary, AB, Canada
Background/Purpose: High quality ambulatory care provision should mitigate avoidable emergency department (ED) visits by persons with inflammatory arthritis (IA) conditions and address the unique realities…

1
2
3
…
35
Next Page »